Tumor Xenograft Model
Tumor Xenograft Model - Related Videos
03:10
In Vivo Fluorescence Imaging to Localize Antibodies in a Mouse Tumor Xenograft Model
0 Views •
2025
The video demonstrates a fluorescence imaging method for in vivo antibody localization in a mouse tumor xenograft model. It involves the injection of tumor cells in a mouse to generate solid xenografts beneath the skin. Subsequent injection of fluorescent antibodies confirms specific localization through enhanced fluorescence signals within the tumor xenograft.
08:03
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
0 Views •
Cited by 59 •
2015
This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in men.
03:56
Tumor Enzymatic Digestion: A Procedure to Generate Tumor Cell Suspension from Patient-derived Xenograft Cancer Mouse Models
0 Views •
2023
This video describes the procedure to obtain tumor cell suspension from patient-derived xenograft or PDX cancer mouse models. Small animal models provide an expeditious, reproducible, and adaptable platform to study tumor progression and different metastatic...
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
0 Views •
Cited by 1 •
2018
Mantle cell lymphoma (MCL) is a difficult to treat B cell disorder and it is equally difficult to establish a xenograft mouse model of primary MCL to study and develop therapeutics. Here, we describe the successful establishment of MCL xenografts in mice to help understand its underlying biology.
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
0 Views •
Cited by 16 •
2015
Human multiple myeloma (MM) cells require the supportive microenvironment of mesenchymal cells and extracellular matrix components for survival and proliferation. We established an in vivo chicken embryo model with engrafted human myeloma and mesenchymal cells to study effects of cancer drugs on tumor growth, invasion and angiogenesis.
FAQs
Immunodeficiency reduces the host’s ability to reject implanted human tumor cells or tissue, allowing engraftment and continued proliferation. This compatibility makes it possible to observe tumor formation and treatment responses within a living animal rather than only in cell culture. The same feature also limits conclusions about interactions between the tumor and a fully functioning immune system.
The surrounding animal microenvironment can affect how a human tumor grows and responds to therapy. Although xenografts may retain selected features of the original malignancy, the host environment is not identical to the patient’s body. Consequently, growth patterns or drug responses observed in vivo require careful interpretation before they are considered predictive of clinical outcomes.
A Tumor Xenograft Model connects cellular observations with outcomes that occur in an intact animal. Researchers can examine whether tumor cells proliferate into a measurable mass and whether a treatment produces a corresponding response in vivo. This added context helps evaluate findings from cell-based studies while exposing differences that may arise from the animal microenvironment.
Researchers can compare therapeutic agents or treatment levels by observing how implanted tumors respond in vivo. Differences in the resulting tumor response support evaluation of dose effects and relative treatment activity. Continued or altered growth despite therapy can also provide a model for investigating mechanisms of drug resistance, while recognizing that the animal setting may not fully reproduce clinical resistance.
A typical workflow begins with implanting human tumor cells or tissue into an immunodeficient animal. The graft is then allowed to engraft and proliferate until it forms a measurable mass. Researchers can administer or compare treatments and follow tumor outcomes in vivo. The resulting observations are interpreted alongside the original tumor features and the model’s biological limitations.
The model provides measurable tumor masses that allow researchers to assess whether human tumor cells have engrafted and proliferated. These masses can then serve as the basis for comparing treatment responses, examining dose-related effects, and identifying differences in therapeutic activity. Such outcomes extend molecular or cell-based findings into an animal-level assessment of tumor behavior.
Tumor xenografts are useful when investigators need to evaluate tumor biology or therapeutic responses in vivo. They support comparisons among treatment agents, examination of dose responses, and investigation of drug resistance mechanisms. In medicine-focused research, the models help bridge laboratory findings and whole-animal outcomes, but differences from human tumors and their native environment must guide interpretation.